Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
Status:
Completed
Trial end date:
2019-06-07
Target enrollment:
Participant gender:
Summary
This study is designed to compare long-term outcomes among patients randomized on the BMT CTN
0702 protocol (NCT01109004), "A Trial of Single Autologous Transplant with or without
Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for
Patients with Multiple Myeloma". It is hypothesized that use of novel anti-myeloma agents
will improve long-term progression-free survival (PFS) after high-dose melphalan followed by
autologous hematopoietic cell transplantation (HCT) as compared to a second autologous
transplantation.
Phase:
Phase 3
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators:
Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI) National Marrow Donor Program